| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.96.3.874 |
| P698 | PubMed publication ID | 9264495 |
| P2093 | author name string | Li G | |
| Weisel RD | |||
| Li RK | |||
| Rao V | |||
| Merante F | |||
| Williams WG | |||
| Mickle DA | |||
| Christakis GT | |||
| Luss H | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypertrophic cardiomyopathy | Q1364270 |
| P304 | page(s) | 874-881 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy | |
| P478 | volume | 96 |
| Q35654989 | 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase |
| Q50769739 | A 7.1 kbp beta-myosin heavy chain promoter, efficient for green fluorescent protein expression, probably induces lethality when overexpressing a mutated transforming growth factor-beta type II receptor in transgenic mice. |
| Q64056424 | Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure |
| Q28348531 | Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy |
| Q79501997 | Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-beta1 in thyroid hormone-induced cardiac hypertrophy |
| Q42757834 | Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation |
| Q79074390 | Antagonistic Effects of TNF-α on TGF-β Signaling Through Down-Regulation of TGF-β Receptor Type II in Human Dermal Fibroblasts |
| Q34358339 | Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair |
| Q39165397 | Boerhaavia diffusa L. attenuates angiotensin II-induced hypertrophy in H9c2 cardiac myoblast cells via modulating oxidative stress and down-regulating NF-κβ and transforming growth factor β1. |
| Q92309063 | Cardiac Chagas Disease: MMPs, TIMPs, Galectins, and TGF-β as Tissue Remodelling Players |
| Q64229554 | Cardiomyocyte SMAD4-Dependent TGF-β Signaling is Essential to Maintain Adult Heart Homeostasis |
| Q52135967 | Cardiopulmonary malformations in the inv/inv mouse. |
| Q24648892 | Cellular and molecular mechanisms of fibrosis |
| Q37502208 | Chemokines and cardiac fibrosis. |
| Q35649473 | Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases |
| Q34245123 | Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor β (TGFβ1)-dependent paracrine mechanism |
| Q42591255 | Deficiency of iNOS Does Not Prevent Isoproterenol-induced Cardiac Hypertrophy in Mice |
| Q52580417 | Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis. |
| Q35078379 | Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction |
| Q36749281 | ECM remodeling in hypertensive heart disease |
| Q30468957 | Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation |
| Q75332642 | Enhanced inflammatory response in neural tubes of embryos derived from diabetic mice exposed to a teratogen |
| Q36383294 | Grape seed proanthocyanidin extract alleviates ouabain-induced vascular remodeling through regulation of endothelial function |
| Q42515078 | Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy |
| Q27339180 | Hypothyroidism and its rapid correction alter cardiac remodeling |
| Q73565002 | Immunohistochemical analysis of platelet-derived growth factor-B expression in myocardial tissues in hypertrophic cardiomyopathy |
| Q41739115 | Increased Transforming Growth Factor-β Levels Associated With Cardiac Adverse Events in Hypertrophic Cardiomyopathy. |
| Q37327651 | Inhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition |
| Q45122645 | Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice |
| Q33586605 | Intramyocardial fibroblast myocyte communication |
| Q48179118 | Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans. |
| Q42019573 | KLF15 and cardiac fibrosis: the heart thickens |
| Q35527297 | Left ventricular systolic dysfunction in asymptomatic Marfan syndrome patients is related to the severity of gene mutation: insights from the novel three dimensional speckle tracking echocardiography |
| Q91229323 | Mechanical regulation of gene expression in cardiac myocytes and fibroblasts |
| Q41864380 | Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice |
| Q37914058 | Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. |
| Q37777001 | New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Chymase as an Important Target to Prevent Organ Damage |
| Q46613174 | Opposite effects of Activin type 2 receptor ligands on cardiomyocyte proliferation during development and repair |
| Q77485079 | Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury |
| Q73313263 | Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy |
| Q73140029 | Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease |
| Q43124445 | Pitavastatin reduces oxidative stress and attenuates intermittent hypoxia-induced left ventricular remodeling in lean mice |
| Q42741838 | Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload |
| Q36931270 | Prevalence of aortic dilation in hypertrophic cardiomyopathy |
| Q35296718 | Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. |
| Q30476541 | Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer |
| Q37428869 | Role of TGF-beta on cardiac structural and electrical remodeling. |
| Q88968512 | Role of cytokines and inflammation in heart function during health and disease |
| Q33801619 | Serum Levels of TGF-beta1, TIMP-1 and TIMP-2 in Patients with Lumbar Spinal Stenosis and Disc Herniation |
| Q47152878 | Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy |
| Q33804142 | TGF-beta and fibrosis |
| Q39737677 | TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. |
| Q63880217 | TGF-β1 Gene polymorphisms in patients with end-stage heart failure |
| Q99587532 | Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? |
| Q99632889 | The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome |
| Q33939892 | The molecular genetic basis for hypertrophic cardiomyopathy |
| Q37161329 | The pathogenesis of cardiac fibrosis. |
| Q35923510 | Tomoregulin-1 prevents cardiac hypertrophy after pressure overload in mice by inhibiting TAK1-JNK pathways |
| Q35946850 | Toxicological effect of TiO2 nanoparticle-induced myocarditis in mice |
| Q37808014 | Transforming growth factor (TGF)-β signaling in cardiac remodeling. |
| Q35209142 | Transforming growth factor beta in cardiovascular development and function |
| Q35895390 | Transforming growth factor beta signaling in adult cardiovascular diseases and repair. |
| Q41521275 | Transglutaminase 2 in human diseases |
| Q47903633 | Upregulation of Cardiac Insulin-like Growth Factor-I Receptor by ACE Inhibition After Myocardial Infarction: Potential Role in Remodeling |
| Q38998926 | Using baculovirus/insect cell expressed recombinant actin to study the molecular pathogenesis of HCM caused by actin mutation A331P |
Search more.